logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Pfizer Tops Estimates in Second Quarter, Reiterates Full Year Outlook

By  +Follow July 30, 2013 8:52AM
Share:
Tickers Mentioned:

Pfizer Inc. (PFE) , the biggest drugmaker in the world, on Tuesday reported second-quarter earnings that nipped past analyst predictions as the company fought through declining sales that were hamstringed by the loss of exclusivity on the blockbuster cholesterol fighter Lipitor.

For the quarter, NYC-based Pfizer said it generated $12.97 billion in revenue, compared to $13.97 billion in the second quarter last year.  Net income soared to $14.1 billion, or $1.98 per share, versus $3.25 billion, or 43 cents per share, in last year’s quarter.  In February, Pfizer spun-out its animal health business into a new company called Zoetis, Inc. (ZTS) .  In December 2012, it sold its nutrition business to Nestle SA ($NSRGY) for $11.85 billion, accounting for most of the surge in reported income.  Excluding gains from the sale, restructuring costs and other special items, adjusted profits for the second quarter totaled $4.0 billion, or 56 cents per share, compared to $4.45 billion, or 59 cents per share, in the year prior quarter.

Wall Street was expecting EPS of 55 cents on revenue of $13.01 billion.

Sales of Lipitor sank 55 percent from $1.22 billion in the second quarter of 2012 to $545 million in the latest quarter.  Sales of pneumococcal vaccine Prevnar slipped 3 percent to $969 million due to changes in government purchasing patterns.  Counterbalancing those losses, sales of Pfizer’s biggest drug Lyrica, which is indicated for fibromyalgia, diabetic nerve pain and more, improved by 10 percent to $1.13 billion.

Revenue for Pfizer’s leading business units – primary care, specialty care, emerging markets and established products – all declined compared to the year prior quarter.  Ian Read, chairman and chief executive at Pfizer, said in today’s statement that he expects emerging market business growth to accelerate in the second of the year, led by China.

“From a total company view, we are tracking to our expectations for the full year and continue to capitalize on the investments we are making to better position Pfizer for long-term success,” added Read.

The company backed its 2013 forecast of adjusted earnings in the range of $2.10 to $2.20 per share.

Sales of anti-cancer drugs rose 24 percent to $399 million, boosted in part by a 191-percent climb in sales of Xalkori to $67 million and $17 million in sales from new drug Inlyta.

Operating margin improved significantly from 29.9 percent to 41.3 percent.

Marking “the next step in Pfizer’s journey to further revitalize [its] innovative core,” Pfizer said on Monday that it intends to split its company into three new units.  One unit will focus on drugs that are patent-protected beyond 2015.  The second will include vaccines, oncology and consumer healthcare products.  The third will include drugs that have lost – or will soon lose – patent exclusivity, generics and future product collaborations.  The changes are slated to start happening in January.

Two new drugs, blood thinner Eliquis and rheumatoid arthritis drug Xeljanz, are thought by many to have the capabilities to grow into blockbusters, although Zeljanz is facing some hurdles in Europe with negative opinions being offered by a European Medicines Agency committee.  Zeljanz generated $33 million in sales in the second quarter. The FDA is reviewing a supplemental New Drug Application (NDA) for Zeljanz with a decision expected by February.  Topline results are expected from two ongoing phase 3 trials evaluating Zeljanz in the second quarter next year.  The FDA is also reviewing a supplemental NDA for Eliquis, with a decision expected by March 15, 2014. 

During the second quarter, Pfizer repurchased $3.3 billion worth of its common stock, bringing its first-half total to $8.7 billion.

Shares of PFE have risen 20 percent so far in 2013 through Monday’s close at $29.54.  

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for PFE
Dmitri Danov
28 Jan 15 05:39:42
couple trades 1/27 live in room $JNUG ss 41.08 cov 40.62.. $PFE 32.80 lg 33.05 out $ADXS ss 9.76 cov 8.81
Sleek Money
28 Jan 15 05:35:47
Pfizer Inc. $PFE Updates FY15 Earnings Guidance http://t.co/tQOHbmh891
ProVesting
28 Jan 15 05:31:12
$PFE: Pfizer Inc. (PFE) Updates FY15 Earnings Guidance: http://t.co/WPaniwTyff
US Consumer News
28 Jan 15 05:11:05
Pfizer's PT raised by Argus to $36.00. buy rating. http://t.co/RCInSLrABB $PFE #PFE
Smarter Analyst
28 Jan 15 05:05:38
Market Scenarios: Winners And Losers http://t.co/jMKwznIA2A $BMY $PFE $PG $SPY $TLT $UUP
Analyst Ratings
28 Jan 15 05:05:36
Pfizer's PT raised by Argus to $36.00. buy rating. http://t.co/lGHKPGoSMC $PFE #PFE
John Turner
28 Jan 15 05:05:05
$PFE Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead http://t.co/5VB0f903se
Irma Doucet
28 Jan 15 05:05:00
$PFE Pfizer's 2015 forecast disappoints, crimped by generics, dollar http://t.co/lQni9k5US6
IH News Desk
28 Jan 15 05:00:11
$BIDU Stock Price Updated Wednesday, January 28, 2015 07:11:10 AM $X $WWE $PFE $PXYN http://t.co/k4PWKbxHvB
InvestorPlace
28 Jan 15 04:55:59
Pfizer Inc.: $PFE Should Finally Punch Its Way Higher http://t.co/VuXZzVeckY
Sentifi US Market
28 Jan 15 04:45:32
Pfizer to pay $400 million to avert investor class action trial http://t.co/uvC6et80PU More about $PFE: http://t.co/Gtb8tWgeFc
Bad * Charts
28 Jan 15 04:45:11
Something is UP with Pfizer? http://t.co/GE7adODnie $PFE
Sentifi US Market
28 Jan 15 04:30:49
TOP 10 Most Discussed $DJIA Companies Today http://t.co/fMrleoGQ4G $CAT $PG $PFE $MSFT $MMM http://t.co/xCH7A00qGs
StockNewsWires
28 Jan 15 04:11:04
$PFE: Healthcare Stocks in Focus - Pfizer (PFE), Gilead Sciences (GILD ...: http://t.co/VOhVgbJStU
PolgarStocks
28 Jan 15 03:55:42
$IYT Reviews Updated Wednesday, January 28, 2015 06:07:23 AM $PFE $GOOG $XOM $OIL http://t.co/t5afe8d1OU
Rosner Stocks
28 Jan 15 03:55:38
$EWT Company Info Updated Wednesday, January 28, 2015 05:59:27 AM $GILD $PFE $BIIB $OIL http://t.co/ENsNmmLPcu
StockNewsWires
28 Jan 15 03:51:05
$LAMR $PFE: Stocks Gaining Momentum: Lamar Advertising Co. (NASDAQ:LAMR ...: http://t.co/naTv3pvQWj
G Bend
28 Jan 15 03:21:35
RT @fwpharma: In the FirstWord newsletter: Q4 results for @bmsnews, @Novartis, @pfizer & more http://t.co/uz6z75uodE $BMY $NVS $PFE #pharma…
12Stocks.com
28 Jan 15 03:01:38
Weekly Dow #Stocks Trend $UTX $MMM $PFE $UNH $MRK $HD $TRV $GE $CVX $DD $BA $WMT $V $CSCO $DIS $NKE $KO $INTC @ http://t.co/TvzJfdisOX
ABMRG
28 Jan 15 02:48:42
@ArmstrongDrew $PFE plans BIG MOVE post $MRK #oncology #deal-To overcome looming off-#patents, dried-up #pipeline #mergersandacquisitions
Langan Stocks
28 Jan 15 02:46:40
$VGZ Reviews Updated Wednesday, January 28, 2015 05:03:23 AM $PXYN $PCLN $A $PFE http://t.co/8lPDSdETIa
TalkMarkets
28 Jan 15 02:33:27
The 5 Best #Dow #Stocks $UNH $HD $MMM $PFE $TRV http://t.co/kQDEOSzXsH
Sentifi US Market
28 Jan 15 02:26:24
The Dollar Did It: Currency Headwinds Hit Pfizer, P&G as Market Slumps http://t.co/piIjYssvSk More http://t.co/8FrP8t6ntR $PFE $PG $USD
Julie-Anne Webb
28 Jan 15 02:15:11
RT @fwpharma: In the FirstWord newsletter: Q4 results for @bmsnews, @Novartis, @pfizer & more http://t.co/uz6z75uodE $BMY $NVS $PFE #pharma…
Thudder & Wicks
28 Jan 15 02:07:42
Deals of the Day: $SYK, $SNN, $AOL, $ICL, $PFE, #OZMinerals http://t.co/RI1JgrCtjt
Caligirl22
28 Jan 15 01:50:30
RT @pharmalot: Pfizer to pay $400M to settle shareholder lawsuit over off-label marketing.. read the old lawsuit here.. http://t.co/dulp5wD…
Marvin Clark
28 Jan 15 01:25:22
A Day On Wall Street: Generally Ugly With Snow Flurries $CAT $FCX $BMY $PFE $DFT $PG $AAL $AAPL http://t.co/uJpSxkpXGn
TalkMarkets
28 Jan 15 01:25:22
A Day On Wall Street: Generally Ugly With Snow Flurries $CAT $FCX $BMY $PFE $DFT $PG $AAL $AAPL http://t.co/lKeHEQ1hNR
Michael Haydock
28 Jan 15 01:22:14
RT @ScripMandy: $BMY $PFE All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings: http://t.co/mS0P3VCJKa (Scrip subscribers)
Colin White
28 Jan 15 01:15:30
RT @ScripMandy: $BMY $PFE All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings: http://t.co/mS0P3VCJKa (Scrip subscribers)
Alysia Sarkisian
28 Jan 15 00:46:08
RT @TheStreet: Blue chips say a strong dollar will cut into 2015's profits. So why are analysts optimistic on Pfizer? http://t.co/T7uD6tDLc…
Media Sentiment
28 Jan 15 00:44:56
$PFE received a new alert. Find out why at http://t.co/5lwmDm2SCs #stocks #daytrading #trading #mkt #NYSE #NASDAQ #markets 9
The GMP Group
28 Jan 15 00:43:42
RT @fwpharma: In the FirstWord newsletter: Q4 results for @bmsnews, @Novartis, @pfizer & more http://t.co/uz6z75uodE $BMY $NVS $PFE #pharma…
Jo Brown
28 Jan 15 00:42:18
RT @fwpharma: In the FirstWord newsletter: Q4 results for @bmsnews, @Novartis, @pfizer & more http://t.co/uz6z75uodE $BMY $NVS $PFE #pharma…
TheStreet
28 Jan 15 00:40:11
Blue chips say a strong dollar will cut into 2015's profits. So why are analysts optimistic on Pfizer? http://t.co/T7uD6tDLcN $PFE
FirstWord Pharma
28 Jan 15 00:38:05
In the FirstWord newsletter: Q4 results for @bmsnews, @Novartis, @pfizer & more http://t.co/uz6z75uodE $BMY $NVS $PFE #pharma #biotech
Mandy Jackson
28 Jan 15 00:25:06
$BMY $PFE All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings: http://t.co/mS0P3VCJKa (Scrip subscribers)
OTPicks.com
28 Jan 15 00:22:31
http://t.co/NYsxQOU64w danrocks: $DIA keeping this on watch $VXX $XLP $PFE $RIG: danrocks http://t.co/3dE5uX7EC7 http://t.co/NYsxQOU64w
OTPicks.com
28 Jan 15 00:22:29
http://t.co/QkCFZ8YF3c danrocks: $DIA keeping this on watch $VXX $XLP $PFE $RIG: danrocks http://t.co/1gT81L1wgf http://t.co/QkCFZ8YF3c
ProTradersNews
28 Jan 15 00:21:04
$PFE: Focus on Pfizer for the Next Pharma Big Deal: http://t.co/VBWAEnQmn1
Dow Stocks
28 Jan 15 00:16:56
#Dow #stocks $PFE Pfizer Daily:-0.61% Weekly:-1.51% YTD:4.65% Trend:65 / 100 http://t.co/eX04HBQkay
PolgarStocks
27 Jan 15 23:51:13
$NSC News Updated Wednesday, January 28, 2015 02:07:21 AM $AA $PFE $GE $RIC http://t.co/elp7tUHlXw
StockNewsWires
27 Jan 15 23:36:03
$PFE: Short Interest of Pfizer Inc. Increases by 7.3%: http://t.co/SDC6sU6DtB
FinSentS SP500
27 Jan 15 23:13:44
$PFE:US Pfizer Hit by Stronger Dollar, Patent Losses, Lawsuit Settlement - #PFIZER INC http://t.co/sIKzT8WVV6 #SP500
PolgarStocks
27 Jan 15 22:49:13
$IWC Filings Updated Wednesday, January 28, 2015 01:07:22 AM $HEMP $FCX $LUV $PFE http://t.co/UWHL8P4tCB
PolgarStocks
27 Jan 15 22:49:08
$PFE Stock Price Updated Wednesday, January 28, 2015 01:07:22 AM $CMG $TBT $MMM $GLD http://t.co/XBHm5Q0IDA
Gotham City Capital
27 Jan 15 22:29:36
@pbmech @GoGoBio We get success with Betrixaban there's no way we DON'T see a buyout.. $BMY $JNJ or $PFE?? $PTLA
Stock Wire
27 Jan 15 22:27:06
PFIZER INC (PFE) Earnings Report: Q4 2014 Conference Call Transcript $PFE http://t.co/iuUJhSbSHR
TalkMarkets Recap
27 Jan 15 22:24:24
The 5 Best #Dow #Stocks $UNH $HD $MMM $PFE $TRV http://t.co/SUvHvhKVPG
Rosner Stocks
27 Jan 15 21:48:11
$XLV Reviews Updated Tuesday, January 27, 2015 11:59:26 PM $XOM $PFE $TBT $BBRY http://t.co/B3YN0bFXLV
				
				
By  +Follow July 30, 2013 8:52AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.